| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Pathology and Laboratory Medicine, University of Pennsylvania, 401 Stellar-Chance Laboratories, Philadelphia, PA 19104;
Department of Pathology, University of Maryland Hospital, Baltimore, MD 21201; and
Laboratory of Molecular Biology, Department of Biology, University of Dayton, Dayton, OH 45469
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
)
(6, 7, 8), and proinflammatory cytokines (IL-6, TNF-) have
been implicated in triggering or regulating this complex phenomenon
through activation of their respective signal transduction pathways
(9, 10). However, the exact molecular events and
mechanisms by which these factors contribute to the regulation of liver
regeneration are still poorly understood. The complement system, a phylogenetically ancient arm of the innate immune response (11), has recently been suggested to play novel roles in regulating noninflammatory processes, including cell proliferation and differentiation during development (12, 13). In this context, it has been recently proposed that complement factors may contribute to the regulation of amphibian limb regeneration, as indicated by the expression of the third component of complement (C3) in the regenerating limb blastema cells of certain urodele species (14). This potential involvement of complement in intricate morphogenetic and developmental processes, including tissue remodeling during limb regeneration and muscle cell differentiation in urodeles (14), provided the basis for an intriguing hypothesis that complement may also have been selected during evolution to participate in the regulation of the regenerative response in higher vertebrates.
To investigate the potential role of complement in mammalian regeneration, we have examined the involvement of complement component C5 in the regenerative response of the liver to injury, using a murine model of CCl4-induced liver toxicity (15) and a congenic strain of mice genetically deficient in C5 (16).
CCl4-mediated liver injury is a well-established model for the study of liver regeneration in rodents (17, 18). It stimulates hepatocyte proliferation and results in both functional and structural restoration of the hepatic parenchyma. Toxin-induced liver injury is associated with free-radical mediated lipid peroxidation and fat deposition in the liver (15). It is mainly characterized by acute hepatocellular necrosis caused by alterations in the permeability of cellular, mitochondrial, and lysosomal membranes (19), and it has recently been shown to induce hepatocyte apoptosis (20).
Here we report that C5-deficient mice show impaired liver regeneration after toxic exposure to CCl4. Moreover, these mice show a significant delay in the entry of their hepatocytes into S phase at 36–48 h after the injury, as indicated by the reduced BrdU incorporation into C5-deficient livers. This defect in hepatocyte proliferation is corrected and normal liver regeneration is restored in these mice after reconstitution with murine C5. The mechanism by which C5 contributes to normal regeneration was delineated using recombinant C5a as well as a specific C5a receptor antagonist.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Fourteen- to 16-wk-old female B10D2oSn-J mice (The Jackson Laboratory, Bar Harbor, ME) were used in this study. The B10D2oSn-J strain bears a 2-bp (TA) deletion in an exon near the 5' end of the C5 gene, which results in the expression of a truncated protein that accounts for the C5 protein deficiency (16). This strain has been generated by backcrossing the C5-deficient DBA/2 strain onto a C57BL/10 background. As a control group, age- and gender-matched wild-type mice of the C5-sufficient B10D2nSn-J strain (The Jackson Laboratory) were used in these experiments.
All mice were housed in the animal facility of the University of Pennsylvania, within a barrier, on a 12-h light/dark cycle. Water and rodent diet were provided ad libitum. Mice were acclimatized for at least 1 wk before the experiments. Studies were conducted in compliance with the guidelines of the University of Pennsylvania, and all experiments were performed in accordance with the animal protocol approved by the University of Pennsylvania Institutional Animal Care and Use Committee.
CCl4 injury
Acute CCl4 liver injury was induced in age- and gender-matched C5-/- and wild-type (C5+/+) mice by the i.p. injection of a single 2-µl/g dose of a 50% (v/v) solution of CCl4 (Sigma, St. Louis, MO) in mineral oil. Four animals in each cohort were sacrificed at various times after injury (0, 24, 36, 48, 72, 96 and 120 h). Livers were harvested, fixed overnight in 10% neutral buffered formalin, and processed for paraffin embedding, sectioning, and histological evaluation (hematoxylin-eosin staining).
BrdU incorporation and immunohistochemistry
5-Bromo-2'-deoxyuridine (BrdU)3 (Sigma) was administered to the mice, 2 h before harvesting of the livers, by i.p. injection, at 50 mg/kg body weight. Paraffin-embedded liver sections were then subjected to immunohistochemical staining using a mouse anti-BrdU mAb (Boehringer Mannheim, Indianapolis, IN) and an avidin-biotin-peroxidase conjugate (Vectastain ABC kit; Vector Laboratories, Burlingame, CA). In brief, paraffin-embedded liver sections were deparaffinized and then rehydrated through a series of alcohol solutions. Antigenic sites were made accessible by denaturation of the tissue in 10 mM citric acid, pH 6.0, and endogenous peroxidase activity was quenched by incubating the slides in a mixture of methanol and H2O2. After successive blocking steps in avidin, biotin, and 4% horse serum/PBS, the tissue was incubated with the primary anti-BrdU Ab (0.2 µg/ml) for 45 min at 37°C. This step was followed by the addition of a secondary biotinylated horse anti-mouse IgG (7.5 µg/ml for 30 min at 37°C), and the subsequent incubation with the avidin-biotin-peroxidase complex (ABC reagent; Vector Laboratories). BrdU reactivity in the tissue sections was detected with the addition of diaminobenzidine. BrdU-positive hepatocytes were identified by their large, round, dark brown-stained nuclei under high-power magnification.
Sections were counterstained with hematoxylin (Gill’s formulation) to localize nonreplicating hepatocytes (with blue-stained nuclei).
Biochemical evaluation of liver injury-serum toxicity markers
Blood was collected by cardiac puncture of metophane-anesthetized mice at various times after CCl4 injury. After clotting, serum was obtained by centrifugation at 14,000 rpm for 5 min, and stored in -70°C until analysis. The extent of liver toxic injury was determined by measuring the degree of elevation of alanine aminotransferase (ALT), aspartate aminotransferase, and total bilirubin in the serum of CCl4-treated mice. All enzymatic assays were performed by Anilytics (Gaithersburg, MD).
Purification of murine C5
Murine C5 was purified from normal mouse serum by a modification of a method previously described (21). Mouse serum (50 ml) (obtained from Cocalico Biologicals, Reamstown, PA) was precipitated with 4% polyethylene glycol (PEG) at 4°C for 30 min in the presence of 20 mM EDTA, 10 mM benzamidine, and 1 mM PMSF. The supernatant collected after centrifugation was further precipitated with 10% PEG. The resulting precipitate after the centrifugation of this mixture (4–10% PEG precipitate) was resuspended in 20 mM NaH2PO4 buffer, pH 7.4, loaded onto a DEAE 40 HR (6.5 x 5.0 cm) anion exchange chromatography column (Millipore, Bedford, MA) and eluted with a linear salt gradient (0–500 mM NaCl). C5-containing fractions were identified by SDS-PAGE, pooled, and dialyzed overnight against PBS, pH 7.4, at 4°C. This C5 pool was subsequently passed through an affinity chromatography column that was prepared by covalently coupling a mouse mAb raised against murine C5 (clone BB5.1) (22) to a cyanogen bromide-activated Sepharose matrix (Pharmacia, Piscataway, NJ). After extensive washing of the column with PBS, the bound protein was eluted with 2 M KBr. The fractions containing C5, which were >99% pure as judged by SDS-PAGE, were immediately pooled and dialyzed overnight against PBS, pH 7.4. This affinity-purified C5 preparation was assayed in a rabbit erythrocyte lysis assay for hemolytic activity mediated through the alternative pathway of complement activation.
Reconstitution of C5-/- mice with murine C5
B1OD2oSn-J (C5-/-) mice were injected i.p. with 150 µg of affinity-purified, hemolytically active, murine C5 in a solution of PBS, 20 min before the administration of CCl4.
The mice were injected with an amount of protein sufficient to yield a reconstituted serum concentration of C5 identical with that of wild-type animals (75–80 µg/ml).
In vivo C5aR blockade using a peptide antagonist
The cyclic hexapeptide AcF[OpdChaWR] was used in this study as a specific C5aR antagonist. Peptide synthesis and cyclization were performed as previously described (23). The peptide was purified using preparative reversed-phase HPLC, and eluted fractions were characterized by mass spectrometry (matrix-assisted laser desorption ionization). For the C5aR blockade study, a cohort of C5-sufficient (B10D2nSn-J) mice received i.v. three successive doses (1 mg/kg body weight, in PBS) of antagonist at 6 h-intervals after CCI4 injury. Mice treated with PBS alone served as a control cohort in this experiment. Both groups were treated i.p. with CCI4, and BrdU incorporation and immunohistochemistry were performed as described above.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
If C5 is an essential component of normal liver regeneration, mice
deficient in this complement protein should exhibit an abnormal
regenerative response to toxic liver injury. Indeed, when we treated
C5-deficient mice and their wild-type (C5+/+)
counterparts with a single dose of CCl4 and
subsequently sacrificed the mice at various times after the challenge,
we found that the livers of C5-/- mice
displayed extensive necrosis and a diffuse pattern of degeneration that
extended throughout the hepatic parenchyma and persisted until 72
h after the injury (Fig. 1
). In contrast,
wild-type mice displayed a localized and almost exclusively
centrilobular pattern of necrosis at 48 h, with the tissue
manifesting definitive signs of recovery and regeneration at 72 h
after the injury. Of particular note was the significant degree of fat
deposition throughout the parenchyma of the
C5-/- livers at 48 and 72 h after injury,
a feature that was almost absent from the
CCl4-treated C5+/+ mice and
indicated that the effect of the hepatotoxin was more pronounced in the
C5-/- animals (Fig. 2, D and F).
|
|
).
Another marked difference between the C5-/- and
the wild-type livers was the presence of increased parenchymal
apoptosis in the wild-type mice during the early stages following
CCl4 exposure (36–48 h), as demonstrated by the
presence of numerous cells with condensed (pyknotic) nuclei and
apoptotic bodies in the centrilobular areas of
hematoxylin/eosin-stained liver sections (Fig. 2, A and
C). The C5-/- livers appeared to
have a significantly lower rate of apoptosis during the first 48
h, whereas extensive cell necrosis due to severe toxicity was prominent
throughout the tissue (Fig. 2, B and D). However,
after 72 h, increased apoptosis was also detected in the
C5-/- livers, comparable to that observed at
earlier stages in the wild-type mice.
To evaluate the extent of toxic injury induced to the liver, in terms
of plasma transaminase activity and hepatic enzyme release, we assayed
sera collected from C5+/+ and
C5-/- mice at various times after injury for
ALT activity (Fig. 3B). A
comparable increase in the levels of serum ALT was observed in both
cohorts at 48 and 72 h after CCl4
administration, indicating that the toxic effect was similar in both
groups and therefore excluding the possibility that the
C5-/- livers may have shown defective
hepatocyte regeneration and a decreased proliferative response due to a
greater protection from toxic damage.
|
BrdU incorporation detected by immunohistochemistry
(24) was used to determine whether the absence of C5
causes abnormalities in the entry of C5-/-
hepatocytes into the S phase (DNA synthesis) of the cell cycle, thus
hindering the regenerative response of the liver after toxic injury.
When a single dose (50 mg/kg) of BrdU was administered i.p. to
CCl4-treated C5+/+ and
C5-/- mice, 2 h before the livers were
harvested, the level of BrdU incorporation in
C5-/- livers was markedly lower than that in
wild-type livers, at both 36 and 48 h after injury (Fig. 3A). Almost no reactivity was detected in
C5-/- hepatocytes, and the very low overall
staining in these livers was attributed to replicating nonparenchymal
cells (Fig. 4). In contrast, the
C5+/+ livers exhibited a normal pattern of BrdU
reactivity, with incorporation into replicating hepatocytes peaking at
36 h after injury and remaining at elevated levels by 48 h
(Fig. 3A). BrdU incorporation in C5+/+
livers decreased to basal levels at 96 h after injury, whereas in
C5-/- livers, a delayed peak was detected at
72 h after CCl4 administration,
corresponding to only 
30% of the wild-type peak BrdU incorporation
at 36 h. These results clearly demonstrate the inability of
C5-/- mice to promote hepatocyte entry into S
phase, a prerequisite for normal liver regeneration in response to
toxic injury.
|
To evaluate the regenerative response in terms of actual mitotic
activity and hepatocyte proliferation, mitotic figures were identified
and counted under a light microscope in hematoxylin/eosin-stained liver
sections of C5-/- and
C5+/+ mice at 48 and 72 h after
CCl4-induced injury. No mitoses were detected in
C5-/- livers at 48 h after injury, in
contrast to the numerous mitoses found throughout the liver parenchyma
of C5+/+ mice at the same time (Fig. 5). The sluggish regenerative response
and delayed tissue repair exhibited by the
C5-/- mice was further substantiated by the
rare occurrence of mitotic hepatocytes, even at 72 h after the
administration of CCl4. These observations are
consistent with the results of the BrdU incorporation time-course
experiments and strongly indicate that C5-/-
mice are incapable of mounting a normal regenerative response to toxic
liver injury induced by CCl4. Furthermore, these
results suggest that C5 may play a critical role in priming normally
quiescent hepatocytes to re-enter the cell cycle and proliferate in
response to toxic injury, by providing essential signaling cues for the
G1-S phase transition in the cell cycle.
|
If defective regeneration and abnormal hepatocyte proliferation
after CCl4 injury is the direct consequence of C5
deficiency and not a secondary defect in the
C5-/- mice, then it should be possible to
correct this defect and restore the regenerative response by
reconstituting C5-/- mice with C5. Therefore,
we treated C5-/- mice with a single dose of
purified, hemolytically active murine C5, 20 min before
CCl4 administration, and then monitored these
mice for hepatocyte BrdU incorporation and corresponding mitotic
activity. Reconstitution of C5-/- mice with
hemolytically active C5 restored BrdU incorporation in hepatocytes, at
48 and 72 h after injury, to nearly 80% of the peak wild-type
levels at 36 h (Fig. 6).
Furthermore, the mitotic indices of the C5-reconstituted mice were
similar to those of the C5+/+ mice, with the
number of mitotic figures (% mitosis) rising to 70% of wild-type
levels at 48 h after injury (Fig. 5). Histologic analysis
indicated that the livers of the C5-reconstituted mice displayed an
injury pattern during the first 48 h that closely resembled that
of the wild-type mice (Fig. 1). The areas of necrotic tissue were
localized around the central veins (centrilobular necrosis) and were
easily distinguished from the surrounding parenchyma, in which
considerable basophilic staining and hepatocyte karyomegaly were
evident. At 72 h after exposure to CCl4 the
C5-reconstituted livers manifested extensive tissue repair, with the
regenerating tissue replacing the previously necrotic areas. These
histologic findings were consistent with the results of the BrdU
immunohistochemistry and together provide considerable evidence to
support a role for C5 as an essential component in normal liver
regeneration after toxic injury.
|
There are a number of mechanisms by which C5 could contribute to
normal liver regeneration. It would be reasonable to propose that its
function is mediated by one or more of its activation products (C5a,
C5b, C5b-9). Therefore, to dissect the mechanism by which C5 mediates
its effect during liver regeneration, we assessed whether C5a, an
activation product of C5, could promote normal liver regeneration and
effectively restore the wild-type (+/+) phenotype
when administered to C5-/- mice that had been
treated with CCl4. Indeed, when
C5-/- mice were injected with three successive
doses (3.5 µg/animal) of human, recombinant C5a, at 6-h intervals
after the exposure to CCl4, hepatocyte BrdU
incorporation was restored to 70% of the peak wild-type levels at
48 h after injury (Fig. 6). However, no effect on hepatocyte DNA
synthesis or proliferation was observed when C5a was administered to a
cohort of C5-/- mice that had not been exposed
to CCl4, strongly indicating that C5a is
specifically involved in the normal regenerative response of the liver.
These findings implicate complement activation as a mechanism that may
contribute to normal liver regeneration, because C5a is generated upon
complement activation and subsequent cleavage of C5 (25).
Furthermore, they support a novel role for the C5a receptor (C5aR) that
is expressed in the liver (26), suggesting that
C5aR-mediated signaling is a critical component of the regenerative
response to liver injury.
C5aR stimulation is required for cell cycle progression in regenerating hepatocytes
C5a may have pleiotropic effects on regenerating hepatocytes. A
requirement for C5a activity during liver regeneration was clearly
demonstrated by reconstituting C5-deficient mice with C5a and restoring
their regenerative phenotype. To determine whether this effect is
exerted through stimulation of the C5a receptor expressed in the liver,
we performed in vivo inhibition studies using a specific C5a receptor
(C5aR) antagonist derived synthetically from the COOH terminus of C5a
(23). This potent antagonist is a small cyclic peptide
that exhibits a C5a inhibitory activity for human leukocytes in the low
nanomolar range, and it has been shown to specifically block
C5a-mediated effects in various rodent models of disease (27, 28). When we treated C5-sufficient mice with this antagonist at
various times after toxic liver injury, BrdU incorporation into
hepatocytes was found to be significantly blunted, indicating a
defective proliferative response to injury that was marked by the
inability of hepatocytes to re-enter the cell cycle (S phase) and
proliferate (Fig. 7). The livers of these
mice showed persistent necrotic damage at 72 h after
CCl4 administration, which was comparable to the
extent of necrosis observed in C5-deficient mice at the same time
point. These results clearly demonstrate that C5aR signaling after C5a
stimulation is essential for liver regeneration and identify the C5a
receptor as a novel regulatory check- point for cell cycle progression
in regenerating hepatocytes.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
receptor I and IL-6-deficient mice in a partial
hepatectomy model of liver regeneration (9, 10). Although
these studies have shown a requirement for these components of the
cytokine network in the early stages of liver regeneration, they point
to a functional redundancy of their signaling pathways later on in the
process. The observation that both C5-deficient and wild-type mice
eventually recover from injury further stresses the concept that the
regenerating liver recruits several interdependent molecular pathways
that act cooperatively, and in a compensating manner, to ensure its
complete recovery from injury. Moreover, it suggests that C5 is one
among essential factors that mediate liver regeneration, and that it
probably exerts its function in an early stage during this process. C5, a serum protein that is an integral component of the complement activation cascade, generates two distinct products upon proteolytic cleavage: C5b, which participates in the assembly of the C5b-9 complex (the membrane attack complex, or MAC) that induces the lysis of complement-targeted cells (25); and the anaphylatoxic fragment C5a, which has a potent chemoattractive effect on various myeloid cells, stimulating the migration of neutrophils, eosinophils, basophils, and monocytes and causing the degranulation of mast cells (29). The pleiotropic effects of C5a on a wide array of tissues are mainly mediated by stimulation of its G-protein coupled receptor C5aR (30).
The ability of C5a to restore the DNA synthetic response and proliferation of hepatocytes in C5-/- mice indicates that this anaphylatoxin may play an important role in normal liver regeneration and that stimulation of its receptor C5aR may trigger signal transduction events that prime quiescent hepatocytes to re-enter the cell cycle. To address this plausible mechanism by which C5 may contribute to liver regeneration and establish that C5aR signaling is an essential component of the pathway leading to mitogenic priming of hepatocytes, we performed in vivo blockade studies using a specific C5aR antagonist. Mice treated with the C5aR antagonist exhibited significantly blunted hepatocyte proliferation after toxic injury, which was marked by a defective S phase transition profile, clearly demonstrating that stimulation of the C5a receptor is required for cell cycle progression in hepatocytes and normal liver regeneration after toxic injury.
Recent studies in a human neuroblastoma cell line have suggested that a fragment of C5a participates in apoptotic signal transduction pathways through binding to the neuronal C5a receptor nC5aR (31). From another perspective, it has been reported that C5a may protect neurons from excitotoxin-induced degeneration and apoptosis, and this neuroprotective function may be mediated by binding of C5a to its neuronal receptor (32). These observations suggest that C5 may contribute to the regulation of the regenerative response of the liver through its activation product, C5a, and that signaling through the C5a receptor, which is expressed in human liver parenchymal cells (26, 33), and in rat liver nonparenchymal cells (34), may elicit a growth factor-like response after liver injury, stimulating hepatocyte DNA synthesis and proliferation. Our data from the C5a reconstitution studies demonstrate that C5a is indeed a critical intermediate in this process. The results of the inhibition studies identify the C5a receptor (C5aR) as a novel regulatory element driving hepatocyte proliferation and therefore provide a mechanism by which C5 and its activation fragment C5a exert a mitogenic effect on hepatocytes.
Binding of C5a to its receptor, found primarily in Kupffer cells (liver macrophages) and hepatic stellate cells (34), could result either in direct stimulation of cell proliferation or in activation of apoptotic pathways leading to the clearance of superfluous or irreversibly damaged cells during the course of regeneration. In this context, it should be noted that we observed very little apoptosis in the C5-/- liver parenchyma within the first 48 h after CCl4 treatment, a feature that could be attributed to the absence of a possible apoptotic stimulus associated with C5 or one of its activation fragments. A similar concept implicating apoptosis as a possible regulatory response of the liver to acute injury was recently discussed in a study involving IL-6-deficient mice (35). Moreover, the significant restoration of hepatocyte proliferation in C5-/- mice, after reconstitution with human C5a, suggests that C5a may also have a direct effect on stimulating cell proliferation during liver regeneration through binding to its receptor C5aR. In support of this plausible mechanism, a recent study has demonstrated that C5a can exert a direct effect on hepatocytes through the inducible expression of C5aR on their surface after treatment with IL-6 (36). A possible induction of C5aR expression in hepatocytes during liver regeneration cannot be excluded because it has been shown that cytokine levels in portal circulation, including those of IL-6, are rapidly elevated after partial hepatectomy or toxic liver injury as part of the hepatic acute-phase response (1).
Another way in which C5 could contribute to the regulation of liver
regeneration is by mediating, as an upstream element, the release from
nonparenchymal cells (bearing C5a receptors) of proinflammatory
cytokines (IL-6, TNF-) that have been shown to be essential for
normal liver growth and regeneration.
Our finding that intact C5a receptor signaling is essential for hepatocyte proliferation in a murine model of liver regeneration can be further explored with the availability of mice that bear targeted disruption of the C5aR gene (37).
In conclusion, the results of this study show that complement, diverging from its established role as an innate defense mechanism against infection, appears to play a novel, integrated role in the maintenance of hepatic homeostasis and the physiological response of the liver to toxic injury.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. John D. Lambris, Protein Chemistry Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6079.
3 Abbreviations used in this paper: BrdU, 5-bromo-2'-deoxyuridine; ALT, alanine aminotransferase; PEG, polyethylene glycol.
Received for publication October 30, 2000. Accepted for publication December 1, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. J. Cell Physiol. 141:503.[Medline]
expression during liver regeneration after partial hepatectomy and toxic injury, and potential interactions between transforming growth factor- and hepatocyte growth factor. Hepatology 18:1422.[Medline]
This article has been cited by other articles:
|
|
 |
|
  M. M. Markiewski, R. A. DeAngelis, C. W. Strey, P. G. Foukas, C. Gerard, N. Gerard, R. A. Wetsel, and J. D. Lambris The Regulation of Liver Cell Survival by Complement J. Immunol., May 1, 2009; 182(9): 5412 - 5418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kambas, M. M. Markiewski, I. A. Pneumatikos, S. S. Rafail, V. Theodorou, D. Konstantonis, I. Kourtzelis, M. N. Doumas, P. Magotti, R. A. DeAngelis, et al. C5a and TNF-{alpha} Up-Regulate the Expression of Tissue Factor in Intra-Alveolar Neutrophils of Patients with the Acute Respiratory Distress Syndrome J. Immunol., June 1, 2008; 180(11): 7368 - 7375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saethre, M. K. J. Schneider, J. D. Lambris, P. Magotti, G. Haraldsen, J. D. Seebach, and T. E. Mollnes Cytokine Secretion Depends on Gal{alpha}(1,3)Gal Expression in a Pig-to-Human Whole Blood Model J. Immunol., May 1, 2008; 180(9): 6346 - 6353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D Metcalfe and M. W.J Ferguson Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration J R Soc Interface, June 22, 2007; 4(14): 413 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Stoick-Cooper, R. T. Moon, and G. Weidinger Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine Genes & Dev., June 1, 2007; 21(11): 1292 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ritis, M. Doumas, D. Mastellos, A. Micheli, S. Giaglis, P. Magotti, S. Rafail, G. Kartalis, P. Sideras, and J. D. Lambris A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways J. Immunol., October 1, 2006; 177(7): 4794 - 4802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nozaki, B. J. Raisler, E. Sakurai, J. V. Sarma, S. R. Barnum, J. D. Lambris, Y. Chen, K. Zhang, B. K. Ambati, J. Z. Baffi, et al. Drusen complement components C3a and C5a promote choroidal neovascularization PNAS, February 14, 2006; 103(7): 2328 - 2333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Anderson, R. Sporici, J. Lambris, D. LaRosa, and A. I. Levinson Pathogenesis of B-Cell Superantigen-Induced Immune Complex-Mediated Inflammation Infect. Immun., February 1, 2006; 74(2): 1196 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Cramer, D. J. Allendorf, J. T. Baran, R. Hansen, J. Marroquin, B. Li, J. Ratajczak, M. Z. Ratajczak, and J. Yan {beta}-Glucan enhances complement-mediated hematopoietic recovery after bone marrow injury Blood, January 15, 2006; 107(2): 835 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Renckens, J. J. T. H. Roelofs, S. A. J. ter Horst, C. van 't Veer, S. R. Havik, S. Florquin, G. T. M. Wagenaar, J. C. M. Meijers, and T. van der Poll Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice J. Immunol., November 15, 2005; 175(10): 6764 - 6771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Addis-Lieser, J. Kohl, and M. G. Chiaramonte Opposing Regulatory Roles of Complement Factor 5 in the Development of Bleomycin-Induced Pulmonary Fibrosis J. Immunol., August 1, 2005; 175(3): 1894 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Koch, A. Kanazawa, R. Nishitai, B. E. Knudsen, K. Ogata, T. B. Plummer, K. Butters, and J. L. Platt Intrinsic Resistance of Hepatocytes to Complement-Mediated Injury J. Immunol., June 1, 2005; 174(11): 7302 - 7309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Lappegard, J. Riesenfeld, O.-L. Brekke, G. Bergseth, J. D. Lambris, and T. E. Mollnes Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production Ann. Thorac. Surg., March 1, 2005; 79(3): 917 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Daveau, M. Benard, M. Scotte, M.-T. Schouft, M. Hiron, A. Francois, J.-P. Salier, and M. Fontaine Expression of a Functional C5a Receptor in Regenerating Hepatocytes and Its Involvement in a Proliferative Signaling Pathway in Rat J. Immunol., September 1, 2004; 173(5): 3418 - 3424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. J. Kim, I. D. Dimitriou, M. C. H. Holland, D. Mastellos, Y. M. Mueller, J. D. Altman, J. D. Lambris, and P. D. Katsikis Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses J. Immunol., August 15, 2004; 173(4): 2524 - 2529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Markiewski, D. Mastellos, R. Tudoran, R. A. DeAngelis, C. W. Strey, S. Franchini, R. A. Wetsel, A. Erdei, and J. D. Lambris C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury J. Immunol., July 15, 2004; 173(2): 747 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, J. D. Lambris, V. Videm, and T. E. Mollnes Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation Ann. Thorac. Surg., March 1, 2004; 77(3): 932 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Otto, H. Hawlisch, P. N. Monk, M. Muller, A. Klos, C. L. Karp, and J. Kohl C5a Mutants Are Potent Antagonists of the C5a Receptor (CD88) and of C5L2: POSITION 69 IS THE LOCUS THAT DETERMINES AGONISM OR ANTAGONISM J. Biol. Chem., January 2, 2004; 279(1): 142 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Strey, M. Markiewski, D. Mastellos, R. Tudoran, L. A. Spruce, L. E. Greenbaum, and J. D. Lambris The Proinflammatory Mediators C3a and C5a Are Essential for Liver Regeneration J. Exp. Med., September 15, 2003; 198(6): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kalant, S. A. Cain, M. Maslowska, A. D Sniderman, K. Cianflone, and P. N. Monk The Chemoattractant Receptor-like Protein C5L2 Binds the C3a des-Arg77/Acylation-stimulating Protein J. Biol. Chem., March 21, 2003; 278(13): 11123 - 11129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Davidson and B. J. Swalla A molecular analysis of ascidian metamorphosis reveals activation of an innate immune response Development, March 12, 2003; 129(20): 4739 - 4751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kimura, M. Madhavan, M. K. Call, W. Santiago, P. A. Tsonis, J. D. Lambris, and K. Del Rio-Tsonis Expression of Complement 3 and Complement 5 in Newt Limb and Lens Regeneration J. Immunol., March 1, 2003; 170(5): 2331 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Grisham and W. B. Coleman Molecular Regulation of Hepatocyte Generation in Adult Animals Am. J. Pathol., October 1, 2002; 161(4): 1107 - 1110. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Cain and P. N. Monk The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg74 J. Biol. Chem., February 22, 2002; 277(9): 7165 - 7169. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
